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Abstract
Background and purpose: The common treatment in patients
with newly diagnosed glioblastoma multiforme is the ultima -
tely radical surgical removal of the tumour combined with ra -
dio therapy. This study compared safety and efficacy of radio-
therapy alone with radiotherapy combined with temozolomide
(TMZ) given before, during, and after radiotherapy.
Material and methods: The patients operated on for glioblas-
toma multiforme during the first 21 postoperative days were
randomly assigned to the group treated with radiotherapy alone
(involved-field radiotherapy in 2 Gy fractions daily five times
a week up to the total of 60 Gy over 6 weeks of treatment) or
to the group treated with radiotherapy and TMZ, initially in
the dose of 200 mg/m2 during 5 postoperative days and after
23 days followed by 75 mg/m2 of body surface area daily, 7 days
a week (from the first to the last day of radiotherapy). On com-
pletion of radiotherapy, five complementary courses of TMZ
were introduced (150-200 mg/m2 for 5 days, repeated every
28 days). The primary outcome measure was overall survival.
Results: Fifty-eight patients from 3 centres were included in
the study. The mean age of patients was 55 years and all the
patients underwent a surgical procedure of glioblastoma re -
moval. The mean overall survival in the group treated with
TMZ was 16.0 months, whereas in the group with radiothe -
rapy alone the overall survival reached 12.5 months. 24-month
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St reszc zen ie
Wstêp i cel pracy: U chorych z nowo rozpoznanymi glejaka-
mi wielopostaciowymi ogólnie przyjêtym postêpowaniem jest
maksymalnie radykalne operacyjne usuniêcie guza uzupe³nio-
ne napromienianiem. W przedstawionym badaniu porówny-
wano radioterapiê jako jedyn¹ metodê leczenia z radioterapi¹
skojarzon¹ z temozolomidem podawanym przed napromie-
nianiem, w jego trakcie i po zakoñczeniu radioterapii, oceniaj¹c
bezpieczeñstwo i skutecznoœæ obu metod terapeutycznych.
Materia³ i metody: Pacjentów operowanych z powodu gleja-
ka wielopostaciowego w ci¹gu 21 dni po zabiegu przydziela-
no losowo do grupy, w której stosowano wy³¹cznie radiotera-
piê (na promienianie na pola wydzielone we frakcjach po 2 Gy
dziennie 5 razy w tygodniu do ca³kowitej dawki 60 Gy w ci¹ -
gu 6 ty godni leczenia), lub grupy leczonej napromienianiem
i temozolomidem, pocz¹tkowo w okresie pooperacyjnym 
200 mg/m2 przez 5 dni, nastêpnie po 23 dniach dawk¹ 
75 mg/m2 powierzchni cia³a dziennie przez 7 dni w tygodniu
(od pierwszego do ostatniego dnia radioterapii). Po zakoñ -
czeniu napromieniania prowadzono piêæ uzupe³niaj¹cych kur-
sów leczenia temozolomidem (150–200 mg/m2 przez 5 dni
po wtarzanymi co 28 dni). G³ówn¹ miar¹ wyniku leczenia by³
ca³kowity czas prze¿ycia.
Wyniki: Do badania w³¹czono 58 chorych z 3 oœrodków. 
Me diana wieku pacjentów wynosi³a 55 lat, wszyscy chorzy byli
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Introduction
High-grade gliomas – glioblastoma multiforme and
anaplastic astrocytoma – account for more than 20% of
brain tumours in adults. According to current know-
ledge, median time of survival after diagnosis does not
exceed 12 months, and even in the presence of favour able
outcome predictors, most patients die within 24 months
[1-3].
The current standard of care involves maximally ra -
dical surgical excision of the tumour followed by post-
operative radiotherapy. Various forms of chemotherapy
combined with surgery and radiotherapy are used in 
case of recurrence or in clinical trials. So far, adjuvant
chemotherapy has not shown unequivocal improvement
of the efficacy of treatment in comparison to the standard
therapy that combines surgery and radiotherapy. Despite
the advances in surgical techniques, introduction of new
methods of radiotherapy and various chemo therapeutic
regimens, the prognosis in high-grade glio mas remains
poor, and the improvement of survival after chemothe-
rapy is modest [2,4-6].
There is an ongoing search for new chemotherapy
and radiotherapy methods that might improve the effi-
cacy of treatment in those neoplasms [2,7].
Recently, temozolomide (TMZ) has been introduced
to clinical use as a method of treatment in glia-derived
brain neoplasms [2,7,8]. 
Clinical trials conducted in many departments as -
sessed various chemotherapy regimens combined with
radiotherapy. None of the phase III randomized trials
that assessed the efficacy of nitrosourea-derived com-
pounds as adjuvant therapy showed substantial improve-
ment of the long-term survival when compared with
radiotherapy alone as the only adjuvant treatment after
surgery [9]. Several studies showed a higher percent-
age of long-term survival in patients who received addi-
tional chemotherapy [10,11].
Temozolomide is an oral alkylating agent, a deriva-
tive of imidazotetrazine with a broad spectrum of anti-
neoplastic activity. So far, TMZ has been shown to be
efficacious in the treatment of patients with glio blastoma
recurrence, in whom other therapies have failed [12].
Both theoretical and clinical presumptions suggest that
the use of that drug in the early phase of treatment, when
the vascularization of the tumour is not com promised,
bioavailability is adequate, and chemo-resistance does
not occur, might improve the efficacy of treatment.
Therefore, the concomitant use of TMZ and radio-
therapy may decrease the number of active clonogenic
cells more efficiently than any of those methods alone.
Synergic action of radiotherapy and TMZ was shown
in experiments performed with human glioma cell cul-
tures. It might be expected that the use of radiotherapy
and TMZ may delay the recurrence and prolong the
progression-free period.
Preliminary reports suggest that the use of TMZ 
(200 mg/m2 of body-surface area daily for five days, each
28 days) before radiotherapy in 33 patients with malignant
gliomas not suitable for surgery or partially resected led to
a positive response to therapy in 17 patients (52%). A pre-
vious publication reported a positive res ponse after the
treatment in 30% of patients. Moreover, the chemothe-
rapy applied directly after surgery might be more effica-
cious than the same treatment used in case of recurrence,
because it acts on a smaller volume of the tumour.
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survival reached 23% in patients treated with TMZ and 6.7%
in those who received radiotherapy only. Haematological com-
plications of third or fourth degree were present in 10% of
patients treated with radiotherapy and TMZ.
Conclusions: The introduction of TMZ before, during and
after radiotherapy for newly diagnosed glioblastoma multi-
forme gives clinically and statistically significant improve-
ment of survival with unremarkably increased toxicity of the
treatment. 
Key words: brain tumour, glioblastoma, temozolomide, radio-
therapy.
operowani z powodu glejaka wielopostaciowego. Mediana cza-
su prze¿ycia w grupie otrzymuj¹cej temozolomid wynios³a 
16 miesiêcy, natomiast wœród otrzymuj¹cych radioterapiê 
12,5 miesi¹ca. Prze¿ycie 24-miesiêczne osób w grupie skoja-
rzonego leczenia wynios³o 23%, natomiast w ramieniu kon-
trolnym – 6,7%. Powik³ania hematologiczne 3. lub 4. stopnia
pojawi³y siê u 10% otrzymuj¹cych radioterapiê ³¹cznie z temo-
zolomidem.
Wnioski: Podawanie temozolomidu przed radioterapi¹, w jej
trakcie i po radioterapii u chorych na nowo rozpoznanego
glejaka wielopostaciowego w istotny klinicznie i statystycznie
sposób wyd³u¿a prze¿ycie przy niewielkim zwiêkszeniu to-
ksycznoœci leczenia.
S³owa kluczowe: guz mózgu, glejak wielopostaciowy, temo-
zolomid, radioterapia.
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So far, the TMZ regimen has included the use of
150-200 mg/m2 for five consecutive days in cycles repeat-
ed every 28 days. Some centres adopted quite a safe re -
gimen of daily therapy with TMZ given in the dose of
75 mg/m2 up to 7 weeks [7,13]. The abovementioned
concentration of the drug [14] substantially inhibits the
activity of O6-methylguanine-DNA methyltransferase
(MGMT), the enzyme involved in DNA repair [15].
This situation might be important, because of the report-
ed association between low activity of MGMT in tumour
cells and the longer survival of patients with glioblastoma
multiforme treated with additional regimens of chemo -
therapy with nitrosourea derivatives [16,17].
Material and methods
Patients
This study included patients aged between 17 and 70
with newly diagnosed and histopathologically confirmed
glioblastoma multiforme (World Health Organization
[WHO] grade IV). Neuropathological examination was
required for all patients. The definite histopathological
diagnosis was established centrally by a single neuro pa -
thologist.
Other inclusion criteria consisted of the surgical re -
moval of the tumour (regardless of the extent of the resec-
tion), time from surgery to randomization (after histopa -
thological confirmation of the diagnosis) < 21 days, age
between 17 and 70, WHO performance scale ≤ 2, and
Karnofsky scale > 60. Patients could not be treated with
corticosteroids within 14 days before randomization, and
could not receive radiotherapy and/or chemotherapy 
previously. The results of biochemical studies (complete
blood count, renal function, liver function) assessed 
within 14 days before randomization should be normal. 
The required values of the laboratory studies were as fol-
lows: total neutrophil count ≥ 1.5 × 109/L; platelet count
≥ 100 × 109/L, serum creatinine ≤ 1.5 times the upper
limit of normal for the laboratory, total serum bilirubin 
≤ 1.5 times the upper limit of normal for the laboratory,
AST or ALT < 2.5 times the upper limit of normal for
the laboratory, and alkaline phosphatase < 2.5 times the
upper limit of normal for the laboratory.
Exclusion criteria consisted of chronic viral hepati-
tis B or hepatitis C virus infection, disorders potentially
affecting the oral ingestion of the medication, e.g. com-
mon vomiting, partial ileus, concomitant or previous
malignancy, except for surgically cured carcinoma in situ
of the cervix or skin. Pregnancy in women at childbear-
ing age was excluded with urine-based pregnancy tests
or with serum beta-human chorionic gonadotropin mea-
surements within 72 hours after randomization.
The patient’s informed consent for the treatment
within the clinical trial conditions was required before
randomization. All patients signed the informed con-
sent for participation in the study, and the study proto-
col was approved by the ethical committee of each par-
ticipating centre.
Study design and treatment
Patients who fulfilled the criteria were randomly
assigned at a 1 : 1 ratio either to radiotherapy alone or
to TMZ and radiotherapy. Randomization was per-
formed in the Department of Neurosurgery and Paedi-
atric Neurosurgery in Lublin. Treatment ought to start
within the week after randomization (Fig. 1).
Radiotherapy
Conventionally fractionated external beam radio-
therapy starting between 44 and 74 days after surgery 
Temozolomide as adjuvant treatment for glioblastoma multiforme
Fig. 1. Patients’ treatment 
Radiotherapy alone Temozolomide (TMZ) + radiotherapy
TMZ after radiotherapy
TMZ 150-200 mg/m2 for 5 consecutive days,
designated as days 29-33 (five such courses, 
expected treatment time – 20 weeks). 
One treatment cycle included days 1-27.
Radiotherapy
Total dose: 60 Gy (30 × 2 Gy)
Assumed time of radiotherapy: 
6 weeks
TMZ + radiotherapy
Radiotherapy
Total dose: 60 Gy (30 × 2 Gy)
Assumed time of radiotherapy: 6 weeks
TMZ: 75 mg/m2 daily for the whole
radiotherapy period (no longer than 7 weeks)
TMZ before radiotherapy
(first week after randomization)
200 mg/m2 for 5 consecutive days
3-week break
Four weeks after the last irradiation
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(2 Gy per fraction) was applied five times a week for 
6 weeks to the total dose of 60 Gy (30 × 2 Gy). Radio-
therapy was applied using three-dimensional planning
techniques, and with megavolt apparatus; the dose was
specified according to the ICRU 50 (International Com-
mission of Radiation Units and Measurements) recom-
mendations. Radiotherapy required linear accelerators
generating X photons at the lowest nominal energy of 
4 MV. Dose rate at the reference point was at least 0.5 Gy
× min-1. Only one planning target volume (PTV) was
used during one cycle of radiotherapy. PTV was deter-
mined ac cording to the results of preoperative comput-
ed tomo graphy (CT) or magnetic resonance imaging
(MRI). PTV had to involve the tumour volume enhanc-
ing after contrast injection and 2-to-3-cm margins.
In patients with gross total excision and dislocation
of the tumour bed in relation to the preoperative imag-
ing, the location of the tumour bed was indicated by 
the site investigators according to their experience, with
2-3-cm margins. The high-dose area could not involve
eye-balls, optic nerves, optic chiasm, nasopharynx or
auditory canals.
Treatment with temozolomide
After allocation to treatment with TMZ and radiothe-
rapy, TMZ was given for five consecutive days (200 mg/
m2) in the week following randomization. After three
weeks, TMZ was given orally (75 mg/m2) daily for 
6 weeks, starting on the day when the radiotherapy had
begun. Then, four weeks after the last radiotherapy frac-
tion, TMZ was continued daily in 5-day cycles (first
cycle: 150 mg/m2; next cycles: 200 mg/m2) every four
weeks for five cycles. Antiemetic prophylaxis with 5-HT3
antagonists was recommended before the first dose of
TMZ. Antiemetic prophylaxis with 5-HT3 antagonists
was used quite rarely during the treatment with low-dose
TMZ concomitant to the radiotherapy. The prophyla xis
of pneumonia due to Pneumocystis carinii infection was
required in all patients treated with TMZ during radio-
therapy. The complete blood count was required within
72 hours before radio- and chemotherapy. The treatment
could be initiated if the total neutrophil count was at least
1.5 × 109/L, and the platelet count was at least 100 ×
109/L. The daily dose of TMZ was 75 mg/m2.
The severity of chemotherapy-related complications
was assessed according to the National Cancer Institute
Common Toxicity Criteria, in which the severity of adverse
events was rated as: 1 – mild, 2 – moderate, 3 – severe,
and 4 – life-threatening. The complete blood count had
to be obtained 21 days (± 47 hours) after the first dose of
each maintenance cycle. The most common adverse events
related to treatment with TMZ include haematological
toxicity (leukopenia, lymphopenia, thrombocytopenia and
anaemia), nausea and vomiting, renal failure, abnormal
activity of liver enzymes, somnolence, rash, constipation,
fatigue, anorexia, hyperglycaemia, and diarrhoea.
Patients receiving radiotherapy were examined by 
the physician once a week. Stage assessment was required
at the fourth week (day 21-27) after the beginning of
radiotherapy. Patients receiving TMZ concomitantly to
radiotherapy were assessed once a week for four weeks
after the end of radiotherapy. Assessment consisted of his-
tory-taking and complete blood count evaluation. The next
assessment was performed 21-27 days after the end of
radiotherapy (given alone or with TMZ). During the fol-
low-up and during the adjunctive treatment with TMZ,
monthly visits were recommended. The same schema of
the clinical assessment was used in both treatment arms.
Clinical evaluation within this study was required in the
following periods: the fourth week (day 21-27) after the
last chemotherapy session and every three months until
death. The evaluation consisted of physical (including 
neurological) examination, WHO/ECOG performance
status, Mini-Mental State Examination, quality of life
questionnaire, MRI or CT (two years after the surgery,
the frequency of imaging studies was left at the discretion
of the investigator; the assessment schema had to be the
same in both treatment arms). Corticosteroids were given
accord ing to the recommendations of the treating physi-
cian. The use of granulocyte colony stimulating factor for
the increase of neutrophil count was not allowed. The use
of erythropoietin was not contraindicated. No other drug
currently being tested in clinical trials was allowed. Sur-
gical decompression (osteoclastic craniotomy), other forms
of chemotherapy, immunotherapy or biological therapy
could not be applied. Neither stereotactic radiotherapy nor
brachytherapy could be planned. If such treatment was
necessary, the patient would not receive further treatment
with TMZ according to the protocol of the study. In case
of tumour progression, the decision on further manage-
ment was made by the treating physician.
Evaluation methods
The main outcome measure was the time of overall
survival. The other assessed outcomes included progre -
ssion-free survival, rates of survival after 6, 12, 18 and
24 months, safety of treatment and the quality of life.
Survival time was the interval between the date of the
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surgery and death. Progression was diagnosed when cli -
nical symptoms and signs of progression occurred (wor -
sening of neurological status) and the imaging (CT or
MRI) showed an increase of the volume of the tumour
> 25%. The progression-free period was defined as the
interval between the date of the surgery and either the
diagnosis of progression or death. Occurrence and se -
verity of toxicity were compared using the Kruskal-Wal-
lis test. Analysis of treatment toxicity was performed 
separately for the first stage of chemotherapy, just before
the beginning of radiotherapy, for radiotherapy alone 
(up to the 28th day after the last radiotherapy session or to
the first day of therapy with TMZ), as well as for adju-
vant therapies. Adverse events of radiotherapy were
assessed 4 weeks after the last radiotherapy session and
graded according to the Common Toxicity Criteria (CTC)
system.
Haematological disturbances were assessed according
to the complete blood count test performed weekly. Nadir
was calculated for each treatment cycle and graded accord-
ing to the CTC scale. Non-haematological adverse events
were assessed and registered separately for each treatment
cycle and graded according to the CTC scale.
Results
Patients
The first patient was randomized on 26 October
2003, and the last patient was randomized on 30 Sep-
tember 2005. Lublin centre recruited 37 patients (in-
cluding 21 treated with TMZ), Warsaw centre recruit-
ed 13 pa tients (including 4 treated with TMZ), and
Krakow centre recruited 8 patients (including 3 treated
with TMZ). Patients were randomly assigned to treat-
ment with radiotherapy only (n = 28) or radiotherapy
combined with TMZ (n = 30). The baseline charac-
teristics of patients in both groups before treatment were
similar (Table 1).
Median age was 55 years. At the time of randomi -
zation, patients did not receive corticosteroids. The dia -
gnosis of glioblastoma multiforme was confirmed in 
58 patients.
Patients’ disposition and treatment characteristics
Median time from randomization to the first course
of TMZ before radiotherapy was 7 days (range, 1–14).
Median time from randomization to the onset of radio-
therapy was 43 days (range, 33–62). Interruptions dur-
ing the radiotherapy were quite brief, and interruptions
due to treatment toxicity were noted in 5% of control
arm patients and in 6% of intervention arm patients.
Fourteen out of the 28 patients completed the full
treatment cycle (one chemotherapy course before the
radio therapy, chemotherapy + radiotherapy, and five
additional chemotherapy courses). Three patients com-
pleted four courses of chemotherapy after radiotherapy,
three others finished their treatment after three courses
of chemotherapy, and one patient after one course of
chemotherapy. Four patients had radiotherapy with
chemotherapy only, and three others finished their treat-
ment with the first course of radiotherapy and did not
even start the radiotherapy. Median age of patients in this
group was 55 years.
After completion of radiotherapy, 21 patients in the
TMZ arm (75%) started adjuvant treatment, and 50%
Radio-  Radio-
therapy therapy
+ temozo-
lomide
Age [years]; median (range) 56 (20-68) 55 (18-65)
Age group; n (%)
< 50 years 5 (17) 4 (14)
> 50 years 25 (83) 24 (86)
Sex; n (%)
Men 16 (53) 18 (64)
Women 14 (47) 10 (36)
Performance status (WHO), n (%)
0 14 (47) 11 (39)
1 12 (40) 15 (54)
2 2 (6) 2 (7)
Extent of tumour resection; n (%)
Total resection 18 (60) 18 (64)
Partial resection 12 (40) 10 (36)
Time from randomization to onset 48 (38-65) 43 (32-62)
of radiotherapy [days]; median (range)
Baseline MMSE score; n (%)
30 14 (47) 13 (46)
27-29 12 (40) 11 (39)
< 26 3 (10) 3 (11)
Unavailable 1 (3) 1 (4)
Table 1. Baseline characteristics of patients
WHO – World Health Organization; MMSE – Mini-Mental State Examination
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of patients completed one planned full course of adju-
vant chemotherapy.
The main reason for abandoning treatment was tu -
mour progression.
In two patients (7%), the treatment was discontinu ed
due to adverse events, i.e. haematological toxicity. The dose
of TMZ was increased to 200 mg/m2 in all patients, start-
ing from the second course of chemothe rapy.
Survival and progression
The follow-up until the last fatality lasted 33 months.
All 58 patients died within this period. Median time 
of overall survival in the combined treatment arm was
16.0 months and was significantly longer than in the
control treatment arm (12.5 months, p < 0.05, Cox 
F-test). The probability of 24-month survival was 23.1%
in patients receiving TMZ + radiotherapy and 6.7% in
patients treated with radiotherapy alone; 18-month 
survival was noted in 30.8% and 23.3%, respectively; 
12-month survival was recorded in 65.4% and 63.3%,
respectively; and 6-month survival was noted in 92.3%
and 86.7%, respectively. Median progression-free time
was 7.5 months in patients treated with TMZ + radio-
therapy and 5.0 months in patients receiving radiothe -
rapy alone.
Adverse events
An analysis of adverse events was performed for the
entire period of treatment (from inclusion in the study
to tumour progression or to the last observation), and
separately for the radiotherapy period (with or without
TMZ) and for the adjuvant chemotherapy period. No
haematological toxicity of third or fourth grade was not-
ed among patients receiving radiotherapy alone.
In patients receiving both TMZ and radiotherapy,
neutropenia of grade 3 or 4 did not occur but throm-
bocytopenia of grade 3 or 4 was noted in one patient
(3%). Haematological complications of grade 3 or 4
were noted therefore in one patient (3%). In patients
receiving additional courses of TMZ, neutropenia of
grade 3 or 4 did not occur but thrombocytopenia of
grade 3 or 4 was noted in two patients (7%). Haemato-
logical complications of third or fourth grade were not-
ed therefore in two patients (7%). Severe infections
before, during or after radiotherapy did not occur in any
patient in either group.
The most common non-haematological adverse event
during the irradiation was moderate or severe general-
ized weakness and nausea, noted in 10 (33%) patients
within the control arm and in 8 (29%) patients treated
with TMZ.
Treatment after the diagnosis of tumour progression
The treating physician decided on further treatment
if tumour progression was diagnosed. The surgery was
repeated in 10 (36%) patients treated with radiothera-
py and TMZ.
Discussion
Chemotherapy before or during radiotherapy in pa -
tients with malignant gliomas has been studied for sev-
eral decades. As yet, the efficacy of various modes of che -
motherapy has been very limited [18]. Based on good
results of the study by Stupp et al. we performed our own
examination. The results of our study show that the use
of chemotherapy shortly after surgery, and combined
radio- and chemotherapy, significantly prolong the sur-
vival of patients with newly diagnosed glioblastoma mul-
tiforme. The present study included patients with glio -
blastoma only [8]. After the follow-up longer than three
years, the authors noted the more than threefold and clin-
ically meaningful improvement of long-term survival
probability (6.7% in the radiotherapy alone arm and
23.1% in patients receiving both radiotherapy and TMZ).
This finding is in agreement with the conclusions drawn
by Stupp [7,8,19].
The outcome of patients who received radiothera-
py alone was better in our study than in other trials
[4,7-9, 20]. It should be noted, however, that our study
included patients in good clinical condition only, who
did not re ceive corticosteroids during 14 days before
randomization. Such a criterion, according to Stupp’s
conclusion, might be used to exclude patients with poor
prognosis who probably would not benefit from any
kind of thera py [3,7,8]. Patients who lack methylation
of the MGMT promoter might be a group of such poor
prognosis [2]. Methylation of the MGMT promoter
precludes transcription, i.e. production of MGMT,
which may result in the lack of repair in TMZ-alky-
lated DNA [2], and may therefore lead to greater effi-
cacy of TMZ and long er survival of patients with
gliomas. Quite long survival (up to 8 months) after the
diagnosis of tumour progres sion should also be high-
lighted [7,8,21].
The prolonged survival might reflect either the
appropriate inclusion criteria or earlier detection of pro-
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gression due to regularly repeated CT or MRI studies.
Small doses of TMZ given on a daily basis enable al -
most twofold (as compared with the standard schema)
increase of the dose intensity without increase of toxic-
ity [14]. Continuous administration of an alkylating
agent decreases the activity of MGMT [15], which is
an enzyme that may be induced by irradiation and is
required for the repair of DNA damage caused by alky-
lating agents [22].
In vitro studies revealed the synergy between TMZ
and radiotherapy [22,24]. Spontaneous TMZ conver-
sion to active metabolites, and their ability to cross the
blood-brain barrier, favour this kind of treatment. Five
courses of adjuvant chemotherapy were added in this
study to provide adequate exposure to the drug. Toxic-
ity of the adjuvant chemotherapy could be managed
symptomatically. Nausea was treated with standard
antiemetics. Marked bone marrow suppression occurred
in 3 (10%) patients and led to the premature discontin-
uation of treatment in one female patient. During a fol-
low-up longer than three years, we did not observe an
increased incidence of late adverse events in patients
treated according to the studied schema. Late toxicity
may be more problematic in patients with gliomas other
than glioblastoma, with longer survival [7,8].
Conclusion
The administration of TMZ before, during and after
radiotherapy for newly diagnosed glioblastoma multi-
forme results in a clinically and statistically significant
improvement of survival.
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